Morgan Stanley issued buy ratings and price targets on Viking Therapeutics stock on May 27, 2026, with Truist Financial also involved.
6 reports, 1 independent
Updated Aug 6
Gone quiet
- Reports
- 6
- Developments
- 1
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley issued buy ratings and price targets on Viking Therapeutics stock on May 27, 2026, with Truist Financial also involved.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Viking Therapeutics
company in San Diego, United States
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
Related events
- Analyst provides a high price target for Viking Therapeutics stock.
- Viking Therapeutics and NextCure, both clinical-stage biopharma companies, are being compared on affordability and analyst ratings.
- Viking Therapeutics' stock price dropped following a dilutive offering, with the company trading on Nasdaq.